Novo Nordisk reported Q2 2026 adjusted sales of DKK 78.49 billion (up 7% at CER) and adjusted operating profit of DKK 33.39 billion (up 11% at CER); full-year guidance for adjusted revenue and EBIT growth revised to -6% to 0%.
FirstSquawk08/04, 11:41 PM
- Q2 2026 Adj Sales DKK78.49 Bln
- Adj Oper Profit DKK33.39 Bln
- Q2 Adj Sales Up 7% At CER
- Adj Operating Profit Up 11% At CER
Figures as quoted by FirstSquawk
Related assets
Coming up for NOVO
Explore next
Latest NOVO news
Finnhub08/19, 05:10 PM
FirstSquawk08/04, 11:41 PM
MarketWatch07/31, 08:54 PM
Novo Nordisk's stock declined after announcing a Phase 3 trial failure.